Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease

IF 3.5 Q3 Biochemistry, Genetics and Molecular Biology

Journal of Genetic Engineering and Biotechnology Pub Date : 2024-11-20 DOI:10.1016/j.jgeb.2024.100438

Maha Abd El Moneem Elfedawy , Samia Abd El Sadek Elsebai , Hend Mohamed Tawfik , Eman Refaat Youness , Moushira Zaki

{"title":"Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease","authors":"Maha Abd El Moneem Elfedawy , Samia Abd El Sadek Elsebai , Hend Mohamed Tawfik , Eman Refaat Youness , Moushira Zaki","doi":"10.1016/j.jgeb.2024.100438","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Chronic kidney disease (CKD) is a chief worldwide health concern that has a substantial financial impact on health systems, high rates of mortality and morbidity as well as cardiovascular disease (CVD) is a major cause of mortality in this population. Adropin is a unique hormone encoded by the energy homeostasis-associated (Enho) gene.</div></div><div><h3>Aim of the work</h3><div>We aimed to explore the efficacy of adropin as a diagnostic candidate biomarker for CVD in patients with CKD.</div></div><div><h3>Methods</h3><div>This is prospective study was carried out on 60 patients (Pt) with CKD and 30 age and sex matched healthy control subjects. CKD Pt were classified according to the history of CVD into two groups: Group A, Pt without history (n = 32) and Group B, Pt with history (n = 28). Serum adropin, lipids and Hs-CRP were measured by ELISA kit. Echocardiography was also investigated. Receiver operator characteristic curve (ROC) was used to determine cut-off points of adropin. Negative predict value (NPV), negative predict value (NPV) and area under curve were detected.</div></div><div><h3>Results</h3><div>There were abnormal ECGs in 78.6 % of CKD patients. Adropin was significantly decreased in Group B than Group A and control group. On the other hand, serum lipids and Hs-CRP were significantly increased in Group B than Group A and control group. ROC analysis revealed that serum adropin could be used to discriminate between patients with and without CVD history at a cutoff level of > 304 with 46.4 % sensitivity and 84.4 % specificity, 74.8 % PPV, 61.2 % NPV and AUC = 0.57. Moreover, between Group A and control at a cutoff level of < 410, with 93.8 % sensitivity, 86.7 % specificity, 87.6 % PPV and 93.3 % NPV and AUC = 0.97 as well as between Group B and control group at a cutoff level of < 416, with 57.1 % sensitivity, 83.3 % specificity, 77.4 % PPV and 66 % NPV and AUC = 0.65.</div></div><div><h3>Conclusion</h3><div>Particularly in CKD patients, adropin may be a useful biomarker for predicting the onset of CVD. Adropin may represent a novel and useful blood marker for assessing systolic function and Spontaneous coronary artery dissection (SCAD).</div></div>","PeriodicalId":53463,"journal":{"name":"Journal of Genetic Engineering and Biotechnology","volume":"22 4","pages":"Article 100438"},"PeriodicalIF":3.5000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Genetic Engineering and Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1687157X24001410","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Chronic kidney disease (CKD) is a chief worldwide health concern that has a substantial financial impact on health systems, high rates of mortality and morbidity as well as cardiovascular disease (CVD) is a major cause of mortality in this population. Adropin is a unique hormone encoded by the energy homeostasis-associated (Enho) gene.

Aim of the work

We aimed to explore the efficacy of adropin as a diagnostic candidate biomarker for CVD in patients with CKD.

Methods

This is prospective study was carried out on 60 patients (Pt) with CKD and 30 age and sex matched healthy control subjects. CKD Pt were classified according to the history of CVD into two groups: Group A, Pt without history (n = 32) and Group B, Pt with history (n = 28). Serum adropin, lipids and Hs-CRP were measured by ELISA kit. Echocardiography was also investigated. Receiver operator characteristic curve (ROC) was used to determine cut-off points of adropin. Negative predict value (NPV), negative predict value (NPV) and area under curve were detected.

Results

There were abnormal ECGs in 78.6 % of CKD patients. Adropin was significantly decreased in Group B than Group A and control group. On the other hand, serum lipids and Hs-CRP were significantly increased in Group B than Group A and control group. ROC analysis revealed that serum adropin could be used to discriminate between patients with and without CVD history at a cutoff level of > 304 with 46.4 % sensitivity and 84.4 % specificity, 74.8 % PPV, 61.2 % NPV and AUC = 0.57. Moreover, between Group A and control at a cutoff level of < 410, with 93.8 % sensitivity, 86.7 % specificity, 87.6 % PPV and 93.3 % NPV and AUC = 0.97 as well as between Group B and control group at a cutoff level of < 416, with 57.1 % sensitivity, 83.3 % specificity, 77.4 % PPV and 66 % NPV and AUC = 0.65.

Conclusion

Particularly in CKD patients, adropin may be a useful biomarker for predicting the onset of CVD. Adropin may represent a novel and useful blood marker for assessing systolic function and Spontaneous coronary artery dissection (SCAD).

查看原文本刊更多论文

慢性肾病患者心血管疾病的候选诊断生物标志物--阿托品

背景慢性肾脏病（CKD）是全球主要的健康问题，对卫生系统造成了巨大的经济影响，死亡率和发病率都很高，心血管疾病（CVD）也是导致这一人群死亡的主要原因。阿托品是一种由能量平衡相关（Enho）基因编码的独特激素。方法这项前瞻性研究的对象是 60 名 CKD 患者（Pt）和 30 名年龄和性别匹配的健康对照受试者。根据心血管疾病史将 CKD 患者分为两组：A 组，无病史的患者（32 人）；B 组，有病史的患者（28 人）。用 ELISA 试剂盒检测血清阿托品、血脂和 Hs-CRP。同时还进行了超声心动图检查。采用接收者运算特征曲线（ROC）确定阿托品的临界点。结果78.6%的 CKD 患者心电图异常。与 A 组和对照组相比，B 组的阿托品明显减少。另一方面，与 A 组和对照组相比，B 组的血脂和 Hs-CRP 明显升高。ROC 分析显示，在 > 304 的临界值下，血清阿托品可用于区分有心血管疾病史和无心血管疾病史的患者，灵敏度为 46.4%，特异度为 84.4%，PPV 为 74.8%，NPV 为 61.2%，AUC = 0.57。此外，A 组与对照组之间的临界值为 410，灵敏度为 93.8%，特异度为 86.7%，PPV 为 87.6%，NPV 为 93.3%，AUC = 0.97；B 组与对照组之间的临界值为 416，灵敏度为 57.1%，特异度为 83.3%，NPV 为 93.3%，AUC = 0.97。结论特别是在慢性肾脏病患者中，阿拖品可能是预测心血管疾病发病的有用生物标志物。阿托品可能是评估收缩功能和自发性冠状动脉夹层（SCAD）的一种新型、有用的血液标记物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Genetic Engineering and Biotechnology Biochemistry, Genetics and Molecular Biology-Biotechnology

CiteScore

5.70

自引率

5.70%

发文量

159

审稿时长

16 weeks

期刊介绍： Journal of genetic engineering and biotechnology is devoted to rapid publication of full-length research papers that leads to significant contribution in advancing knowledge in genetic engineering and biotechnology and provide novel perspectives in this research area. JGEB includes all major themes related to genetic engineering and recombinant DNA. The area of interest of JGEB includes but not restricted to: •Plant genetics •Animal genetics •Bacterial enzymes •Agricultural Biotechnology, •Biochemistry, •Biophysics, •Bioinformatics, •Environmental Biotechnology, •Industrial Biotechnology, •Microbial biotechnology, •Medical Biotechnology, •Bioenergy, Biosafety, •Biosecurity, •Bioethics, •GMOS, •Genomic, •Proteomic JGEB accepts